What are the recommended treatment options for fungal infections, including superficial, mucosal, dermatophyte, systemic candidiasis, invasive aspergillosis, and cryptococcal meningitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment of Fungal Infections

For invasive candidiasis, start with an echinocandin (caspofungin, micafungin, or anidulafungin) for moderately severe to critically ill patients or those with recent azole exposure; use fluconazole for less critically ill patients without recent azole exposure. 1, 2

Systemic Candidiasis (Candidemia and Invasive Candidiasis)

Initial Therapy Selection

The choice between echinocandins and fluconazole depends on illness severity and azole exposure history:

Echinocandins (preferred for most patients):

  • Caspofungin: 70 mg loading dose, then 50 mg daily
  • Micafungin: 100 mg daily
  • Anidulafungin: 200 mg loading dose, then 100 mg daily
  • Use for: moderately severe to severe illness, recent azole exposure, or high risk of fluconazole-resistant species (C. glabrata, C. krusei) 1, 2

Fluconazole:

  • Loading dose: 800 mg (12 mg/kg), then 400 mg (6 mg/kg) daily
  • Use for: less critically ill patients without recent azole exposure and likely susceptible isolates 1, 2

Species-Specific Adjustments

Once species identified, tailor therapy:

  • C. albicans: Transition from echinocandin to fluconazole once clinically stable with susceptible isolate 1, 2
  • C. parapsilosis: Fluconazole preferred (echinocandins have higher MICs); if echinocandin started, consider switching to fluconazole 2, 3
  • C. glabrata: Continue echinocandin; do not switch to fluconazole without susceptibility confirmation 2, 3
  • C. krusei: Echinocandin or liposomal amphotericin B; voriconazole as step-down option 2, 3

Essential Management Steps

  • Remove all intravascular catheters when feasible (strong recommendation for non-neutropenic patients) 1, 2
  • Obtain follow-up blood cultures at 48-72 hours, then every other day until clearance documented 2
  • Duration: 14 days after documented clearance from bloodstream AND resolution of symptoms 1, 2
  • Neutropenic patients: Treat for 2 weeks after clearance AND neutropenia resolution 2, 3

Site-Specific Invasive Candidiasis

CNS Candidiasis:

  • Liposomal amphotericin B (5 mg/kg daily) with or without flucytosine for initial therapy
  • Step-down to fluconazole 400-800 mg daily after response with susceptible isolates
  • Remove infected CNS devices
  • Continue until all symptoms, CSF abnormalities, and radiologic findings resolve 2, 3

Endophthalmitis:

  • Fluconazole 800 mg loading, then 400-800 mg daily (for susceptible isolates)
  • Consider intravitreal injection (amphotericin B or voriconazole) plus systemic therapy for macular involvement or vitritis
  • Vitrectomy for vitritis
  • Duration: 4-6 weeks or until lesion resolution 2

Endocarditis:

  • Liposomal amphotericin B plus flucytosine OR echinocandin for initial therapy
  • Valve replacement mandatory; antifungal therapy ≥6 weeks post-surgery
  • Long-term suppression for patients who cannot undergo valve replacement 2

Mucosal Candidiasis

Oropharyngeal Candidiasis:

  • Fluconazole 100-200 mg daily for 7-14 days (first-line)
  • Alternatives: nystatin suspension, itraconazole 200 mg daily 3

Esophageal Candidiasis:

  • Fluconazole 400 mg daily for 14-21 days until clinical improvement
  • Alternatives: echinocandin (for C. krusei or refractory cases) 2, 3

Invasive Aspergillosis

Voriconazole is the primary therapy for invasive aspergillosis across all sites 4, 2

Treatment by Site

Invasive Pulmonary Aspergillosis:

  • Primary: Voriconazole (loading dose 6 mg/kg IV q12h for 2 doses, then 4 mg/kg IV q12h; oral: 200 mg q12h)
  • Alternative: Liposomal amphotericin B (5 mg/kg daily) 2, 4, 2
  • Duration: minimum 6-12 weeks, varies by immunosuppression degree and disease improvement 2
  • Surgical resection indicated for lesions near great vessels/pericardium, chest wall invasion, or persistent hemoptysis 2

CNS Aspergillosis:

  • Voriconazole (preferred due to excellent CNS penetration)
  • Alternative: Liposomal amphotericin B
  • Surgical resection if feasible
  • Monitor for drug interactions between voriconazole and anticonvulsants 2, 3

Invasive Sinonasal Aspergillosis:

  • Similar to pulmonary aspergillosis
  • Critical caveat: Start with polyene (amphotericin B) if mucormycosis cannot be excluded until definitive diagnosis
  • Surgical debridement as adjunctive treatment 2

Important Considerations

  • Echinocandins are not recommended as primary monotherapy but effective in salvage therapy 2
  • Primary combination therapy not routinely recommended; consider for salvage in immunocompromised patients when surgery not feasible 2
  • Posaconazole approved for salvage therapy (not primary) 4

Cryptococcal Meningitis

Induction therapy with liposomal amphotericin B plus flucytosine is the standard of care 2

  • Induction: Liposomal amphotericin B 5 mg/kg daily + flucytosine
  • Consolidation: Fluconazole after clinical response
  • Aggressive management of elevated intracranial pressure is critical - can lead to vision/hearing loss, facial palsy, and early mortality 2
  • HIV patients: Delay antiretroviral therapy initiation to reduce immune reconstitution inflammatory syndrome risk 2

Mucormycosis

Liposomal amphotericin B is the primary therapy; surgical debridement is mandatory 2

  • Primary: Liposomal amphotericin B 5 mg/kg IV daily (consider up to 10 mg/kg daily in selected cases before surgery or when surgery not feasible)
  • Alternative: Amphotericin B deoxycholate 1.0-1.5 mg/kg IV daily
  • Salvage: Posaconazole (various formulations with different dosing)
  • Surgical resection mandatory except in disseminated cases 2
  • Control underlying conditions (diabetes, immunosuppression) essential 2

Dermatophyte and Superficial Infections

Most superficial fungal infections respond to topical antifungals unless extensive or resistant 5, 6

  • Onychomycosis: Often requires systemic therapy with terbinafine, itraconazole, or griseofulvin
  • Tinea infections (corporis, cruris, pedis): Topical azoles (clotrimazole, miconazole) or allylamines (terbinafine)
  • Tinea capitis: Requires oral griseofulvin or itraconazole (topicals insufficient)

Critical Pitfalls to Avoid

  1. Do not use fluconazole empirically in critically ill patients or those with recent azole exposure - resistance risk too high
  2. Do not delay catheter removal in candidemia - significantly impacts mortality 7
  3. Do not use echinocandins as monotherapy for aspergillosis - inadequate efficacy 2
  4. Do not start azoles for sinonasal infection without excluding mucormycosis - azoles ineffective against mucormycosis 2
  5. Do not use monotherapy with flucytosine - resistance develops rapidly 2
  6. Perform susceptibility testing when treatment fails or prior antifungal exposure exists 2
  7. In pregnancy: Amphotericin B deoxycholate is treatment of choice (azoles contraindicated) 2

References

5
Research

Therapy of common superficial fungal infections.

Dermatologic therapy, 2004

Related Questions

What is the safest first‑line topical therapy for a superficial skin infection when both bacterial and fungal organisms are suspected, appropriate for adults and children over two years without known allergies and safe in pregnancy?
What antifungal treatment is recommended for a patient with a fungal infection on the arm, considering their medical history and potential for complications?
For a patient being treated with voriconazole for an invasive fungal infection, what is the recommended total duration of antifungal therapy in months?
What is the appropriate prescription for treating a deep invasive fungal infection in an adult?
As a primary‑care clinician who sees many skin rashes and is not a dermatologist, how can I empirically treat them with topical antifungals, triamcinolone, or oral prednisone without a definitive diagnosis and know when to refer?
Can lamotrigine (Lamictal) cause easy bruising or muscle tenderness?
Can compartment syndrome be detected on ultrasound?
Can thalassemia minor cause an elevated red blood cell count with normal hemoglobin and hematocrit in a mixed‑race adult with normal mean corpuscular volume?
What are the age‑related (senescent) changes seen on imaging studies?
Can elevated alanine aminotransferase (ALT) and aspartate aminotransferase (AST) cause an elevation in cardiac troponin levels?
How long does it take to see the full clinical effect of fluoxetine?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.